Human Genome Sciences Reports Progress With Late-Stage Products and New I...(ent risk factor forCHD and ischemic stro...),Health

Date:5/28/2008

ent risk factor for CHD and ischemic stroke. Changes in biomarkers suggested a possible reduction in systemic inflammatory burden. In addition, GSK stated in February 2008 that the results of its randomized Phase 2/3 imaging trial of darapladib in coronary artery disease will be presented and published in the second half of 2008.

SYNCRIA(R): POSSIBLE PHASE 3 DECISION IN 2008

Syncria (albiglutide) is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. Syncria is generated from the genetic fusion of human albumin and GLP-1, a peptide hormone that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. GSK is developing Syncria as a treatment for type 2 diabetes mellitus, and initiated a randomized Phase 2b dose-ranging clinical trial of Syncria in May 2007 in patients with type 2 diabetes. As a comparison, one group of patients is receiving Byetta (exenatide).

HGS is entitled to fees and milestone payments, some of which have already been received, that could amount to as much as $183 million, in addition to single-digit royalties on worldwide sales if Syncria is commercialized. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance Syncria to Phase 3 development.

HGS ANALYST DAY WEBCAST

HGS senior executives will provide an overview of the Company at its Analyst and Investor Meeting today in New York, starting at 12 noon Eastern time. The presentations will be webcast and may be accessed at http://www.hgsi.com. Investors interested in listening to the live webcast should log on before the presentations begin in order to download any software required. The archive of the presentations will be available for several days following the meeting.

ABOUT HUMAN GENOME SCIENCES

The mission of HGS is to app
'/>"/>

SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent